[Remote] Senior Director, Pricing & Reimbursement at Dyno Therapeutics

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Advanced degree (PhD, PharmD, MD, or MBA) in a relevant field
12+ years of experience in pharmaceutical/biotech industry with significant leadership experience
Strong leadership skills
Broad understanding and deep experience of global pharmaceutical markets (US & global markets)
Proven track record of bringing products to market successfully

Responsibilities

Lead the development and implementation of global pricing and market access strategies for late-stage and early pipeline products
Collaborate cross-functionally with HEOR, R&D, Program Teams, Commercial, Medical Affairs, and other teams
Develop and communicate compelling value story narratives and messaging for payers, HTA bodies, and other stakeholders
Develop market access and pricing strategies to optimize product value and patient access globally
Ensure integration of market access and pricing strategies into clinical development plans, brand plans, launch strategies, and launch sequencing decisions
Provide pricing guidance and assumptions for strategic planning, annual forecasting, and brand budget processes
Develop resources and materials for local teams to engage with market access stakeholders
Collect actionable insights through market research, expert input forums, advisory boards, early payer advice, and engagement with external stakeholders
Represent the company externally on pricing and market access topics with payers, policymakers, and industry groups
Build, lead, and coach a high-performing global pricing and reimbursement team
Represent Dyne pricing and market access on key senior-level governance forums, working groups, and teams
Understand and abide by global compliance regulations

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Watertown, MassachusettsHeadquarters

2018Year Founded

$106MTotal Funding

SERIES_ACompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.

Manufacturing bottlenecks could hinder scaling of Dyno's operations.

Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.

Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.

Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.

Collaboration with NVIDIA enhances biological sequence design for gene therapies.

Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free